Latest News about REGN
Recent news which mentions REGN
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
November 18, 2024
Tickers
REGN
From Benzinga
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
November 15, 2024
From Benzinga
28 Analysts Have This To Say About Regeneron Pharmaceuticals
November 14, 2024
Tickers
REGN
From Benzinga
2 Top Growth Stocks to Buy on the Dip
November 14, 2024
From Motley Fool
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease
November 13, 2024
From Benzinga
Assessing Regeneron Pharmaceuticals's Performance Against Competitors In Biotechnology Industry
November 06, 2024
From Benzinga
Is It Time to Buy October's Worst-Performing Nasdaq Stocks?
November 06, 2024
From Motley Fool
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
November 05, 2024
From Benzinga
This Is What Whales Are Betting On Regeneron Pharmaceuticals
November 04, 2024
Tickers
REGN
From Benzinga
Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?
October 31, 2024
From Benzinga
Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
October 31, 2024
From Benzinga
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
October 30, 2024
From Benzinga
EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss
October 28, 2024
From Benzinga
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
October 28, 2024
From Motley Fool
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
October 25, 2024
From Benzinga
$100 Invested In This Stock 15 Years Ago Would Be Worth $5,800 Today
October 24, 2024
From Benzinga
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
October 23, 2024
From Benzinga
From Benzinga
Here's How Much $100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth Today
October 10, 2024
From Benzinga
What the Options Market Tells Us About Regeneron Pharmaceuticals
October 10, 2024
Tickers
REGN
From Benzinga
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
October 09, 2024
From Benzinga
Inquiry Into Regeneron Pharmaceuticals's Competitor Dynamics In Biotechnology Industry
October 09, 2024
From Benzinga
Regeneron Chief Flags Health Risks with Popular Weight-Loss Medications Like Ozempic, Says Company Targets Muscle Preservation For Its Obesity Drugs
October 07, 2024
From Benzinga
Should You Buy the Dip on This Top Growth Stock?
October 05, 2024
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.